JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

By M. Kudo, O. Matsui, N. Izumi, H. Iijima, M. Kadoya, Y. Imai, T. Okusaka, S. Miyayama, K. Tsuchiya, K. Ueshima and 6 more. Liver Cancer, 2014

601 citations recorded by the source corpus.

The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan. Three important items have been updated: the surveillance and diagnostic algorithm, the treatment algorithm, and the definition of transarterial chemoembolization (TACE) failure/refractoriness. The most important update to the diagnostic algorithm is the inclusion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a first line surveillance/diagnostic tool. Another significant update concerns removal of the term “lipiodol” from the definition of TACE failure/refractoriness.

Subfields: Cancer Research, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/b8537f05f8e0758437c4982eea0f250804418201

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Llovet
2. Jordi Bruix1 , 2
3. R. Finn
4. M. Kudo
5. M. Sherman

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. R. Finn
4. F. Piscaglia
5. M. Kudo
6. A. Cheng
7. Riccardo Lencioni
8. M. Sherman

Citations in the corpus

• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, methodology): “In a study of 87 Japanese NASH patients with HCC, Yasui et al. [59] found that 56% of cases were noncirrhotic, and it was noted that males developed HCC at a less advanced stage of liver fibrosis than females.”
• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017, background): “%] in %]), and diarrhoea (12 patients [3”
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, methodology): “This study did not enroll patients with >50% liver involvement and main portal vein invasion 330 because this exclusion criterion was used in the preceding phase 2 proof-of-concept study conducted in 331 Japan as mandated by Japan Society of Hepatology consensus-based clinical practice guidelines.(1”